Cytori Therapeutics Coverage Initiated at Roth Capital (CYTX)
Analysts at Roth Capital began coverage on shares of Cytori Therapeutics (NASDAQ:CYTX) in a research report issued to clients and investors on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.
Cytori Therapeutics (NASDAQ:CYTX) opened at 2.39 on Tuesday. Cytori Therapeutics has a one year low of $2.09 and a one year high of $4.93. The stock has a 50-day moving average of $2.44 and a 200-day moving average of $2.51. The company’s market cap is $160.7 million.
Cytori Therapeutics (NASDAQ:CYTX) last announced its earnings results on Thursday, August 8th. The company reported ($0.16) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.13) by $0.03. The company had revenue of $6.00 million for the quarter, compared to the consensus estimate of $2.88 million. Analysts expect that Cytori Therapeutics will post $-0.41 EPS for the current fiscal year.
Separately, analysts at Zacks downgraded shares of Cytori Therapeutics (NASDAQ:CYTX) from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, July 16th. They now have a $2.90 price target on the stock.
Cytori Therapeutics, Inc develops cell therapies based on autologous adipose-derived stem and regenerative cells (NASDAQ:CYTX) to treat cardiovascular disease and repair soft tissue defects.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.